Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421839 | 1.00 | CYP3A4 (0.46) | CYP3A4TSHRALDH1A1SMN1; SMN2ALOX15 | |
| SCHEMBL7082410 | 0.84 | MAPT (0.52) | CYP3A4TSHRALDH1A1SMN1; SMN2ALOX15 | |
| SCHEMBL1242454 | 0.83 | MAPT (0.51) | CYP3A4TSHRALDH1A1SMN1; SMN2ALOX15 | |
| SCHEMBL3780677 | 0.82 | CYP3A4 (0.48) | CYP3A4TSHRALDH1A1SMN1; SMN2ALOX15 | |
| SCHEMBL6927527 | 0.79 | ALDH1A1 (0.54) | CYP3A4TSHRALDH1A1ALOX15TDP1 | |
| SCHEMBL31533760 | 0.79 | GAA (0.39) | CYP3A4TSHRALDH1A1ALOX15TDP1 | |
| SCHEMBL6310104 | 0.79 | GAA (0.39) | CYP3A4TSHRALDH1A1ALOX15TDP1 | |
| SCHEMBL7931554 | 0.79 | EPAS1 (0.42) | CNR2MAP2SLC6A4AVPR2GPR27 | |
| SCHEMBL2544959 | 0.78 | ALDH1A1 (0.46) | CYP3A4TSHRALDH1A1TDP1MAPT | |
| SCHEMBL15611319 | 0.76 | CNR2 (0.39) | CNR2MAP2SLC6A4AVPR2GPR27 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410170-B2 | 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds | ARCUS BIOSCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| US-20230024302-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230024302-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2022-12-08 | — | — | US | disclosed |
| EP-3980010-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | Arcus Biosciences, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| WO-2020247496-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | ARCUS BIOSCIENCES, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | BIONDI RICARDO M | 2007-02-08 | — | — | US | disclosed |
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | BIONDI RICARDO M | 2007-02-08 | — | — | US | disclosed |
| US-20060235192-A1 | Soluble, low dielectrical constant, unsymmetrical polyimide and a method for preparing the same | CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCE (CN) | 2006-10-19 | — | — | US | disclosed |
| EP-1701959-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| EP-1335722-B1 | INDOLYL-SULFONYL- COMPOUNDS USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050176705-A1 | Compounds useful in the treatment of cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-08-11 | — | — | US | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410170-B2 | 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds | PIK3CA, PIK3CG, PIK3CD | CYP3A4 3613/4885TSHR 3567/4885ALDH1A1 3899/4885 |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | CYP3A4 3767/4885TSHR 4516/4885ALDH1A1 247/4885 |
| US-20230024302-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | PIK3CA, PIK3CG, PIK3CD | CYP3A4 3613/4885TSHR 3567/4885ALDH1A1 3899/4885 |
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | CYP7A1, UGT1A1, CYP2F1 | CYP3A4 75/4885TSHR 3990/4885ALDH1A1 319/4885 |
| US-20050176705-A1 | Compounds useful in the treatment of cns disorders | SLC18A2, CNR2, TPH2 | CYP3A4 1428/4885TSHR 1733/4885ALDH1A1 1596/4885 |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | MCL1, MKI67, BAX | CYP3A4 3767/4885TSHR 4516/4885ALDH1A1 247/4885 |
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | CYP3A4 143/4885TSHR 577/4885ALDH1A1 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.